Literature DB >> 22413760

CD133 immunomagnetic separation: effectiveness of the method for CD133(+) isolation from umbilical cord blood.

Iordanis Pelagiadis1, Konstantinos Relakis, Lida Kalmanti, Helen Dimitriou.   

Abstract

BACKGROUND AIMS: Umbilical cord blood (UCB) is a rich source of stem cells, the characterization and isolation of which requires specific stem cell markers and reliable and reproducible protocols.
METHODS: We assessed CD133 isolation in 39 UCB samples, using a commercial immunomagnetic cell-sorting protocol, and, because of its non-reproducibility, we applied optimized protocols in an effort to improve it. These included extra-labeling of the selected CD133(+) subpopulation and indirect labeling using anti-phycoerythrin (PE) microbeads, goat anti-mouse IgG microbeads or a combination of both. The CD34 isolation was used as a control.
RESULTS: The mononuclear cell fraction expressed 0.53±0.06% CD133. The corresponding value for CD34 was 1.64±0.15%. Following the manufacturer's instructions, the CD34 isolation resulted in a population expressing 93±1.25% CD34 while, after the corresponding process, CD133(+) expression ranged from 10% to 85% (median 60%). The optimized isolation protocols did not result in improved CD133(+) yield. The variation in the purity of the CD133 population cannot be attributed to the different clones of CD133 used, because they do not cross-block, while other factors such as glycosylation, which could possibly interfere, do not apply in normal hematopoietic stem cells (HSC).
CONCLUSIONS: CD34 isolation by the immunomagnetic method results in highly pure CD34(+) population, while the efficient and reproducible yield of a pure CD133(+) population is not feasible. Therefore quantification of the positive cells should follow each isolation procedure in order to confirm the number of CD133(+) cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22413760     DOI: 10.3109/14653249.2012.663487

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  6 in total

1.  miR-146a and miR-150 promote the differentiation of CD133+ cells into T-lymphoid lineage.

Authors:  Parviz Fallah; Ehsan Arefian; Mahmood Naderi; Seyed Hamid Aghaee-Bakhtiari; Amir Atashi; Katayoun Ahmadi; Abbas Shafiee; Masoud Soleimani
Journal:  Mol Biol Rep       Date:  2013-05-15       Impact factor: 2.316

2.  Human Chorionic Villous Mesenchymal Stem Cells Modify the Functions of Human Dendritic Cells, and Induce an Anti-Inflammatory Phenotype in CD1+ Dendritic Cells.

Authors:  F M Abomaray; M A Al Jumah; B Kalionis; A S AlAskar; S Al Harthy; D Jawdat; A Al Khaldi; A Alkushi; B A Knawy; M H Abumaree
Journal:  Stem Cell Rev Rep       Date:  2015-06       Impact factor: 5.739

3.  Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta.

Authors:  M H Abumaree; M A Al Jumah; B Kalionis; D Jawdat; A Al Khaldi; A A AlTalabani; B A Knawy
Journal:  Stem Cell Rev Rep       Date:  2013-02       Impact factor: 5.739

4.  Humoral activity of cord blood-derived stem/progenitor cells: implications for stem cell-based adjuvant therapy of neurodegenerative disorders.

Authors:  Edyta Paczkowska; Katarzyna Kaczyńska; Ewa Pius-Sadowska; Dorota Rogińska; Miłosz Kawa; Przemysław Ustianowski; Krzysztof Safranow; Zbigniew Celewicz; Bogusław Machaliński
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

5.  Phenotypic and Functional Characterization of Mesenchymal Stem/Multipotent Stromal Cells from Decidua Basalis of Human Term Placenta.

Authors:  F M Abomaray; M A Al Jumah; K O Alsaad; D Jawdat; A Al Khaldi; A S AlAskar; S Al Harthy; A M Al Subayyil; T Khatlani; A O Alawad; A Alkushi; B Kalionis; M H Abumaree
Journal:  Stem Cells Int       Date:  2016-02-10       Impact factor: 5.443

6.  The effect of human placental chorionic villi derived mesenchymal stem cell on triple-negative breast cancer hallmarks.

Authors:  Alaa T Alshareeda; Emad Rakha; Ayidah Alghwainem; Bahauddeen Alrfaei; Batla Alsowayan; Abdullah Albugami; Abdullah M Alsubayyil; Mohmed Abomraee; Nur Khatijah Mohd Zin
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.